Calithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Calithera Biosciences (NASDAQ:CALA) in a report issued on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Calithera Biosciences Price Performance

CALA stock opened at $0.04 on Friday. The company’s 50 day moving average price is $0.03 and its two-hundred day moving average price is $0.03. Calithera Biosciences has a one year low of $0.01 and a one year high of $0.50.

Institutional Trading of Calithera Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of CALA. Vanguard Group Inc. increased its stake in shares of Calithera Biosciences by 23.4% in the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company’s stock worth $415,000 after buying an additional 26,800 shares during the period. Renaissance Technologies LLC increased its position in shares of Calithera Biosciences by 13.8% in the third quarter. Renaissance Technologies LLC now owns 114,555 shares of the biotechnology company’s stock valued at $337,000 after acquiring an additional 13,855 shares during the period. Alyeska Investment Group L.P. bought a new position in Calithera Biosciences during the 1st quarter valued at approximately $404,000. Goldman Sachs Group Inc. raised its holdings in shares of Calithera Biosciences by 143.2% during the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 72,865 shares in the last quarter. Finally, Affinity Asset Advisors LLC bought a new position in Calithera Biosciences in the 1st quarter worth $404,000.

About Calithera Biosciences

Calithera Biosciences, Inc operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc was incorporated in 2010 and is headquartered in South San Francisco, California.